https://www.avient.com/sites/default/files/2021-06/colormatrix-select-brochure.pdf
COLORMATRIX
SELECT
YOUR CHOICE DELIVERED
REDEFINING
PLASTIC COLORATION
ColorMatrix™ Select Rapid Color Prototyping Technology is a color creation, selection
and supply service for greater control, choice and speed in color development for
injection molded plastic products.
As a cloud-based system, control of your color portfolio is
right at your fingertips.
Some of the information arises from laboratory work with small-scale equipment which may not provide a reliable
indication of performance or properties obtained or obtainable on larger-scale equipment.
https://www.avient.com/sites/default/files/Avient Climate Change Scenario Analysis Summary 2022.pdf
Continued R&D investment in current initiatives is
expected
· Steep increases in advanced economies' carbon prices · Considerable increases in emerging economies' carbon
prices
· Some change in carbon prices
· Declining fuel prices · Regional variability in fuel prices, though slight net
increase
· Rising fuel prices
1
International Energy Agency World Energy Outlook 2021
The following summarizes Avient's climate-related risks and opportunities analyzed across multiple scenarios, in alignment with the Task Force on Climate-Related Financial Disclosures (TCFD) framework.
CLIMATE-RELATED SCENARIOS ANALYZED
Global operations through 2050
PARAMETERS & ASSUMPTIONS
EXCEED
2.5°C
EXCEED
2.0°C
RETURN
BELOW
1.5°C
IMPACT DRIVER &
TIME HORIZON
NET ZERO FUTURE PLEDGING PROGRESS STEADFAST POLICY
Policy & Legal Risk
M L
Carbon pricing exposure in USA, China,
Germany and Spain
Fines and/or compliance measures:
· Clean electrification of operations;
· Emissions intensive equipment phase-out;
· Circular economic and materials efficiency
strategies;
· Net-zero carbon building standards;
· Mandatory energy management systems
and audits
Carbon pricing exposure in USA, China,
Germany, Spain, and Saudi Arabia
Increased fines and compliance measures
related to:
· Phase-outs aligned with Nationaly
Determined Contributions (NDC);
· Renewable energy sourcing;
· Material efficiency standards (minimum
recycled content for packaging, and
enhanced vechicle air quality)
Some regional carbon pricing exposure in
China, Germany and Spain
Technology Risk
S M
Capital expenditures to subsitute emissions
intensive technologies
Declining price point competitiveness
caused by decarbonization pass through
costs
R&D costs to transition to design and deploy
lower-emissions technologies
Slower substitution of materials with lower-
emission options
Market Risk
S M
Declining redundant supply and sourcing
more sustainably causes raw material costs
to rise
Customers demand to lower their scope 3
emissions from purchased goods and
services across all markets
Increasing competition from existing and
unforeseen polymer and non-polymer-
based products that reduce further impact
on climate
Customer behaviors from advanced
economies demand lower carbon products
Rising degree of uncertainty in raw material
prices
Slow customer behavior changes in some
advanced economies
High degree of uncertainty in energy market
signals
Reputation Risk
L
Chemical sector or certain petrochemical
materials (i.e., plastics) stigmatized
Rising expectations for rapid innovation and
displacement of older, heavily carbon-
intensive designs and manufacturing
processes
NDC countries expected to innovate and
seek rapid minimization of customers' scope
3 emissions
Increased concern from stakeholders for not
addressing climate change globally or for
the chemicals sector
Acute & Chronic Risk
L
Possible direct damage to fixed assets and
logistics disruptions in both our value chain
and operations
More frequent and intense weather events
and changing preciptation patterns are likely
to damage manufaturing faciliites, disrupt
logistics and sourcing activities, and
negatively affect employee health and
communities where we operate
More frequent and intense weather events
and changing preciptation patterns are likely
to affect the performance of grids and
thermal plants while pushing up demand for
cooling, damage fixed assets, disrupt
logistics and sourcing activities, and
negatively affect employee health and
communities where we operate
IMPACT DRIVER &
TIME HORIZON
NET ZERO FUTURE PLEDGING PROGRESS STEADFAST POLICY
Resource
Efficiency
Opportunity
S M L
More efficient production and distribution
processes, reduced natural resource usage,
continued use of recycling, and inclusion of
recycled materials in our products such as
reSound
TM
R, ColorMatrix™ Capture™
Oxygen Scavenger, among others will
contribute to increasing product revenues
and reduced operating costs
Resource efficiency efforts supported by
capital allocation in NDC countries is more
likely and may accelerate a path toward
maximizing ROI and reducing operating
costs
Less regulatory and pressure to incentivize
may cause gains from efforts to lag
Energy Source
Opportunity
M L
Use of greater external financing options,
such as operating lease arrangements or
energy performance shared savings
contracts, to source lower emission-energy
and new technologies, such as carbon
capture, utilization & storage (CCUS), in our
operations may reduce operating costs and
maximize returns on investment
Use of lower emission-sources of energy in
operations will lower operating costs and
contribute toward reductions of our scope 1
and 2 emissions and product carbon
intensities
Use of renewable energy, increased
efficiency, and electrification initiatives will
lower operating costs and contribute toward
reductions of our scope 1 and 2 emissions
and product carbon intensities.
Clean electrification of our operations and processes will represent some of our
current scope 1 emissions reductions, though further evaluation is required
https://www.avient.com/products/polymer-additives/barrier-and-scavenger-additives
ColorMatrix™ AAzure™ Acetaldehyde Control Technology for PET
ColorMatrix™ AAzure™ Acetaldehyde Control Technology for PET
ColorMatrix™ AAzure™ Acetaldehyde Control Technology for PET
https://www.avient.com/products/thermoplastic-elastomers/versaflex-pf-tack-layer-surface-protective-films
Explore What's Possible
https://www.avient.com/industries/textiles
Adding value to your supply chain is what we do best, whether it’s with market-leading polymer materials, innovative fiber coloration systems or high-performance screen printing inks.
https://www.avient.com/news/polyone-announces-plans-new-innovation-center-asia
Our „invest to grow‟ strategy in the region is clearly working, and our new Innovation Center is yet another step in what we expect will be continued growth for our customers and PolyOne.”
https://www.avient.com/sites/default/files/2021-10/remafin-ep-white-masterbatches-for-pharma-application-bulletin_0.pdf
KEY CHARACTERISTICS
• Manufactured under change control principles
beyond CAS number (similar level as MEVOPUR
concentrates), reducing risk of change
• Free from animal-derived substances and
phthalates
• Suitable for blown film, injection molding,
blow molding and extrusion
REGULATORY SUPPORT
• Raw materials tested to:
- ISO 10993-1
- USP chapters , including Class VI,
a requirement for ophthalmic and nasal drugs
- European Pharmacopeia 3.1.3/3.1.5
(polyolefin)
- USP (polyethylene)
- ICH Q3D elemental impurities
- USP and USP light transmission
• Registered Drug Master File (Type III)
• Food contact compliance established with
FDA/EU*
APPLICATION BULLETIN
CARRIER
MATERIAL
PIGMENT
CONTENT/TYPE
LIGHT
FASTNESS
THERMAL
STABILITY
PRODUCT
CODE
HDPE 50% TiO2 8 300°C PH00075525
LLDPE 60% TiO2 8 300°C PL00075542
LLDPE 70% TiO2 8 300°C PL00075545
PP 50% TiO2 8 300°C PP00075717
Healthcare use limitations apply—see below.
Some of the information arises from laboratory work with small-scale equipment which may not provide a reliable indication
of performance or properties obtained or obtainable on larger-scale equipment.
Without limiting the generality of this statement, Avient products shall not be used in any medical device application intended for:
(1) exposure to human tissue or body fluids for 30 days or greater;
(2) “plastic” (cosmetic or reconstructive) surgery use;
(3) reproductive implants or any birth control device; or
(4) any critical component in a permanently (greater than 30 days) implanted medical device that supports or sustains human life.
https://www.avient.com/sites/default/files/2022-12/Mevopur Healthcare Colorants and Formulations for Needle Hubs Application Bulletin.pdf
KEY CHARACTERISTICS
• Manufactured at four ISO 13485 certified sites,
providing global consistency and increased
security of supply
• Documented change control beyond CAS
number, reducing risk of change
• Non-phthalate and formulated without
animal-derived substances
• Color can be combined with additives to
enhance performance and protection
REGULATORY SUPPORT
• Raw materials tested to:
- ISO 10993-1 and USP biological
evaluation
- European Pharmacopeia 3.1.3/3.1.5
(polyolefin)
- USP (polyethylene)
- ICH Q3D elemental impurities
• Registered Device Master File
• Food contact established with FDA/EU*
NOMINAL
OUTSIDE
DIAMETER OF
NEEDLE (MM)
COLOR
DESCRIPTION RAL PANTONE
TRANSPARENT
PRODUCT CODE
OPAQUE
PRODUCT
CODE
0.4 Medium Grey 7035 423 C PP7M665125 PP7M665127
0.45 Brown 8017 7588 C PP8M665294 PP8M665296
0.5 Orange 2003 173 C PP2M665298 PP2M665300
0.55 Medium Purple 4005 7676 C PP4M665290 PP4M665292
0.6 Deep Blue 5010 288 C PP5M665894 PP5M665896
0.7 Black 9005 Black C PP9M664950 PP9M664952
0.8 Deep Green 6001 7483 C PP6M665687 PP6M665689
0.9 Yellow 1021 115 C PP1M665211 PP1M665213
1.1 Cream 1015 7401 C PP0M665290 PP0M665292
1.2 Pink 3015 502 C PE3M665725 PP3M665727
Healthcare use limitations apply—see below.
Some of the information arises from laboratory work with small-scale equipment which may not provide a reliable indication
of performance or properties obtained or obtainable on larger-scale equipment.
Please be aware that there are certain applications Avient’s Mevopur products have not been designed for, nor are they promoted or intended for use in: including, but not limited to long-term or permanent
implants, birth control devices, or plastic surgery.
https://www.avient.com/sites/default/files/2023-01/Mevopur Healthcare Colorants and Formulations Special Effects Application Bulletin_0.pdf
KEY CHARACTERISTICS
• Manufactured at four ISO 13485 certified
manufacturing sites, providing global
consistency and increased security of supply
• Documented change control beyond CAS
number, reducing risk of change
• Non-phthalate and formulated without
animal-derived substances
• Available as pre-colored formulation or
concentrate and for use in different polymers
REGULATORY SUPPORT
• Raw materials tested to:
- ISO 10993-1 and USP biological
evaluation
- European Pharmacopeia 3.1.3/3.1.5
(polyolefin)
- USP (polyethylene)
- ICH Q3D elemental impurities
• Registered Drug Master File (Type III) and/or
Device Master File
• Food contact established with FDA/EU**
APPLICATION BULLETIN
* Design note: Effect colors require careful consideration of part design and
polymer flow paths to minimize visible flow lines.
Some of the information arises from laboratory work with small-scale equipment which may not provide a reliable indication
of performance or properties obtained or obtainable on larger-scale equipment.
Please be aware that there are certain applications Avient’s Mevopur products have not been designed for, nor are they promoted or intended for use in: including, but not limited to long-term or permanent
implants, birth control devices, or plastic surgery.
https://www.avient.com/sites/default/files/2022-12/Mevopur Healthcare Functional Additives Medical Devices Application Bulletin.pdf
KEY CHARACTERISTICS
• Manufactured at four ISO 13485 certified sites,
providing global consistency and increased
security of supply
• Documented change control beyond CAS
number reducing risk of change
• Non-phthalate and formulated without animal-
derived substances
• Available for use in a wide range of polymers
including polyolefins, styrenics, polycarbonate
and alloys, polyester, POM
• Functionality can be combined with colorants
into convenient combination concentrates and
ready-to-use formulations
REGULATORY SUPPORT
• Raw materials tested to:
- ISO 10993-1 and USP biological
evaluation
- European Pharmacopeia 3.1.3/3.1.5
(polyolefin)
- USP (polyethylene)
- ICH Q3D elemental impurities
• Registered Drug Master File (Type III) and/or
Device Master File
• Food contact established with FDA/EU*
APPLICATION BULLETIN
* FDA/EU compliance information available upon request
FUNCTIONALITY TARGET APPLICATIONS
DRUG
DELIVERY
DEVICES
SYRINGES &
NEEDLES DIAGNOSTICS CATHETERS
Clarifying PP
Sorbitol-free for transparent
applications with reduced migration
and improved thermal stability
Lubricant—
permanent/
non-migrating
Fast acting reduction in friction
for wide variety of polymers such
as PP, ABS, POM, PC
Protection from
UV in transparent
applications for PP,
PE, PETG, COP
UV blocking in 290-450nm with
no impact on clarity; can be
combined with colors (e.g., amber)
Antistatic ready-to-
use solution for PP,
ABS, PC/ABS
Permanent/non-migrating;
fast decay time independent
of % relative humidity
Gamma/e-beam
sterilization
protection of the
polymer
Preserving the properties of
PP and COC/COP; reduction
in yellowing using Color
Compensation Technology (CCT)
Reduced material
consumption/cycle
time—nucleation
Fast acting new generation
nucleant for PE and PP; improved
thermal and mechanical properties
allows wall thinning; reduction of
tolerance/dimensional problems
between different colors
Laser marking
replacing ink
printing/labels
Solvent-free, high-speed
identification for Nd/YAG laser
for PE,PP, ABS, PC, POM
Antioxidants for
PE, PP, TPE
Thermal protection during
converting/downstream sterilization
Brand protection/
anticounterfeit
Covert and non-covert systems
Healthcare use limitations apply—see below.
Some of the information arises from laboratory work with small-scale equipment which may not provide a reliable indication
of performance or properties obtained or obtainable on larger-scale equipment.
Please be aware that there are certain applications Avient’s Mevopur products have not been designed for, nor are they promoted or intended for use in: including, but not limited to long-term or permanent
implants, birth control devices, or plastic surgery.